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Abstract 
Restoring pluripotency using chemical compounds alone would be a major step forward 
in developing clinical grade pluripotent stem cells, but this has not yet been reported in 
human cells. We previously demonstrated that human amniocytes cultivated with 
valproic acid (VPA_AFS cells) acquired functional pluripotency whilst remaining 
distinct from embryonic stem (hES) cells, questioning the relationship between 
modulation of cell fate and molecular regulation of the pluripotency network. Here, we 
used single cell analysis and functional assays to reveal that VPA treatment resulted in a 
homogenous population of self-renewing non-transformed cells that fulfil hallmarks of 
pluripotency, i.e. a short G1 phase, a dependence on glycolytic metabolism, expression of 
epigenetic modifications on histones 3 and 4, and reactivation of endogenous OCT4 and 
downstream targets at a lower level than that observed in hES cells. Mechanistic insights 
into the process of VPA-induced reprogramming revealed that it was dependent on OCT4 
promoter activation, which was achieved independently of the PI3K/AKT/mTOR 
pathway or GSK3 inhibition, but was concomitant with the presence of acetylated 
histones H3K9 and H3K56, which promote pluripotency. Our data identify for the first 
time the pluripotent transcriptional and molecular signature and metabolic status of 
human chemically-induced pluripotent stem cells.  
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Introduction 
 
The reprogramming of somatic cells to pluripotency was originally pioneered by forced 
expression of transcription factors (TFs) using retroviral transduction1. Alternative 
strategies have since been developed to minimise the number of TFs used2 and to produce 
footprint-free induced pluripotent stem (iPS) cells without genomic alterations3,4. 
Ultimately, the complete replacement of ectopically expressed TFs by chemical 
compounds (CiPS cells) would hold much promise for the use of iPS cells derivates in 
regenerative medicine. To date, this has not yet been achieved in human cells. The two 
major barriers to chemical-based reprogramming are (1) to establish a cocktail of 
mutliple epigenetic modifiers and inhibitors that would reactivate the endogenous 
pluripotent network, and (2) to find a target cell source which chromatin configuration is 
most permissive to such chemical treatments.   
 
Paving the way for the generation of human CiPS cells, iPS cells have been generated 
from human fetal stem cells by ectopically expressing OCT4 alone5,6. This suggests that 
stem cells present during early fetal development may be more amenable to 
reprogramming than terminally differentiated cells found in adult tissues. However, the 
accessibility of the cells is of paramount importance for developing autologous CiPS 
cells. Human amniocytes (amniotic fluid stem cells, i.e. AFS cells) are somatic fetal stem 
cells shed from the fetus in the amniotic fluid and isolated during mid-trimester 
amniocentesis7. Similar to other fetal mesenchymal stem cells (MSCs)8, AFS cells are 
multipotent and differentiate readily into bone, fat and cartilage. They are not 
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tumorigenic, present a low immunogenicity9, and maintain their phenotype and karyotype 
after cryopreservation and in vitro expansion, making them ideal candidates for 
translational use7. AFS cells are characterised by the expression of the standard MSC 
surface markers CD73, CD90 and CD10510,11, along with SSEA4 and CD177. Whilst 
they are not pluripotent and do not express SOX2, NANOG, or OCT4A12-14,9 (the only 
isoform with a pivotal role in self-renewal and pluripotency15), they present a higher 
degree of plasticity compared to adult MSCs, are more rapidly and efficiently 
reprogramed to pluripotency16-18, and are amenable to reprogramming using only OCT46. 
 
We previously reported in two independent studies that human amniocytes cultivated on 
Matrigel in feeder-free hES cell conditions with the histone deacetylase inhibitor valproic 
acid (VPA, 2-propyl pentanoic acid)19, i.e. VPA_AFS cells, gained the capacity to form 
embryoid bodies (EBs) containing cells that expressed ectoderm (NESTIN, PAX6), 
primitive endoderm (BMP4), endoderm (CK3, CK19) and mesendoderm (GATA6) 
markers11-13. When injected subcutaneously into immunodeficient mice, VPA_AFS cells 
formed well-differentiated teratomas within 4-6 weeks, which contained derivatives of all 
three germ layers, as evidenced by immunostaining, i.e. ectoderm (-Tubulin, NESTIN, 
NR1), mesoderm (-ACTININ), and endoderm cells (SOX17, HNF-3, AFP) 11-13. After 
6-8 weeks of in vitro expansion in ESC conditions, VPA_AFS cells (but not AFS cells) 
were capable of differentiating towards the definitive endoderm (CXCR4, SOX17+ and 
HNF-3+, immunostaining) when cultured in serum-free conditions in the presence of 
Activin-A. When cultured in hepatocyte permissive medium, VPA_AFS cells (but not 
AFS cells) also differentiated into ALBUMIN+ AFP+ cells which produced urea. These 
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results show that compared to AFS cells, VPA_AFS cells have a higher developmental 
potential, and suggest that they have acquired functional pluripotency11-13. 
 
However, genome-wide transcriptome analysis of the entire VPA_AFS cell population 
revealed that, despite being clearly separated from AFS cells, they remain different from 
hES cells6-8. This questions the relationship between cell potency and molecular state of 
the pluripotent network. To address this gap in knowledge, we used single cell analysis 
and a range of functional assays to comprehensively characterise VPA_AFS cells and 
understand how they relate to hES cells. We uncover for the first time that human 
amniocytes cultured in hES cell  conditions and treated with VPA aquired some 
molecular, epigenetic and phenotypic features of pluripotency, and that the effect of VPA 
is OCT4A-dependent. We observed a reactivation of endogenous OCT4 and downstream 
targets in all individual VPA_AFS cells (albeit levels were not as high as those found in 
hES cells), resulting in a short cell cycle G1 phase and a dependence on glycolytic 
metabolism. Together, these data indicate that human amniocytes are a candidate cell 
source for developing chemical-based protocols to revert human cells to the naïve 
pluripotent state, which makes it easier to differentiate the cells into any cell type of 
interest. Because of this, naïve stem cells have application in regenerative medicine and 
for disease modelling. 
 
 
RESULTS  
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VPA_AFS cells aquired functional pluripotency but are molecularly different from 
hES cells 
 
The present study characterised the molecular state of the same three AFS cell samples 
which previously formed EBs and teratomas11-13. We first used the colony formation in 
soft agar assay to determine that VPA treatment did not induce the transformation of 
VPA_AFS cells, as evidenced by their inability to show anchorage-independent growth 
(Supplementary Figure 1a). 
Flow cytometry showed that the pluripotency-associated cell surface markers TRA-1-60, 
TRA-1-81 and SSEA3, and the nuclear TFs NANOG and OCT4A were expressed in hES 
cells was and absent in AFS cells but expressed in VPA_AFS cells, albeit plots showed 
overlapping tails with the isotype control for some of these proteins, which indicates the 
population is heterogeneous (Figure 1a). However, scatter plot analysis of the whole 
population transcriptome showed that VPA_AFS cells were molecularly distinct from 
hES cells (r = 0.84), with the heatmap of pluripotency-associated genes showing lower 
expression levels in VPA_AFS cells (Figure 1b).  
 
 
VPA_AFS cells gained OCT4 and NANOG expression with high efficiency 
 
As the results presented above were obtained on the whole population, it is possible that 
the low correlation (r = 0.84) between VPA_AFS cells and hES cells was due to the 
heterogeneity of the AFS cell population to reactivate endogenous OCT4 and NANOG. 
  
7 
To measure the efficiency of the VPA treatment in AFS cells, we introduced OCT4-GFP 
(Cellomics Technology  PLV-10050-50) or NANOG-GFP vectors (Plasmid 21321: PL-
SIN-Nanog-EGFP, Addgene) in order to detect OCT4 and NANOG expression. All three 
AFS cell samples transfected with NANOG-GFP and OCT4-GFP and cultured in D10 
(DMEM + 10% FBS) were negative for cell surface marker TRA-1-60, which is 
considered one of the best markers for human pluripotent stem cells21, but gained TRA-1-
60 expression upon VPA treatment (Figure 2). TRA-1-60+ cells were then single cell 
sorted into four 96-well plates coated with Matrigel (total of 384 cells analysed for each 
condition) and placed in an incubator for an additional 28 days, during which GFP 
expression was monitored 7, 14 and 28 days later using an optical plate reader (Figure 
2a). TRA-1-60 expression was maintained homogeneously in almost all cells (>85% of 
the cell population) over 28 days. Optical analysis of the plates indicated that the cells 
formed clones of variable size all expressing GFP, indicating (1) that VPA treatment 
reactivated OCT4 and NANOG expression, (2) that the acquired phenotype (expression 
of TRA-1-60, OCT4 and NANOG) was stable, and (3) that VPA treatment was highly 
efficient (Figure 2b, 2c). We validated the use of OCT4-GFP lentiviral reporter approach 
by showing that GFP expression correlates with the pattern of OCT4 expression 
demonstrated by immunostaining (Figure 2d). 
 
 
VPA_AFS cells changed cell size, presented a short G1 phase and switched their 
metabolism towards glycolysis  
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As previously demonstrated, VPA_AFS cells grew as compact colonies (Figure 3a), and 
a flow scatter analysis showed that the size of individual VPA_AFS cells was in average 
smaller that the size of the cells from the AFS cell population, i.e. forward scatter (FSC) 
median 278 vs. 809 (10000 cells analysed for each conditions) (Figure 3b), although this 
observation alone does not indicate that the cells are pluripotent.  
 
Propidium iodine staining and flow cytometry analysis of the cell cycle showed that AFS 
cells predominantly presented a distribution typical of diploid DNA content in the G1 
phase of the cell cycle, indicating that the cells were in a pre-replicative state. In contrast, 
VPA_AFS cells showed a shortened G1 phase and a longer S phase (synthesis of DNA) 
for each cycle, which resulted in a shorter G1/S-phase ratio, a feature associated with 
maintenance of the undifferentiated state in pluripotent stem cells22-24, with hES cells 
demosntrating a similar pattern (Figure 3c).  
 
 To determine the metabolic phenotype of VPA_AFS cells, ATP levels were monitored 
dynamically by fluorescence (see Methods). The resistance to oligomycin treatment is 
indicative of a metabolic switch towards glycolysis. Mg provides an index of changing 
ATP concentration and is an indirect read-out for ATP depletion. The drop in ATP is thus 
proportional to the increase in fluorescence. The more prominent is the OXPHOS the 
greater will be the rise in fluorescence consequently plotted. The opposite occurs when 
OXPHOS is scares. Living AFS cells and VPA_AFS cells (1 million cells per sample, 
three samples tested for each group) positively loaded with the MgGreen dye were 
challenged with the chemical inhibitor of the Complex V oligomycin, and changes in 
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fluorescence were recorded and quantified. In AFS cells, but not in VPA_AFS cells, we 
detected a clear and sustained increase in fluorescence within minutes (P<0.05), with the 
graph and chart plotting in corresponding to an increase in depletion (Figure 3d). A 
greater contribution of mitochondria to energy metabolism and an oxidative phenotype 
could account for this increase in fluorescence intensity in AFS cells.  
We next examined mitochondrial oxidative metabolism using carbon dioxide (13CO2) 
production as a marker, as 13C-pyruvate is produced by glycolysis and then oxidized in 
the mitochondria to yield 13CO2. After 4 h incubation with [U-
13C]-D-glucose, 13CO2 
released in the culture medium and in the sealed culture flasks air was measured. 
Compared to AFS cells (undifferentiated and differentiated down the osteoblast lineage), 
VPA_AFS cells demonstrated a significantly (P<0.05) lower production of 13CO2 
(P<0.05), which is indicative of a lower oxidative metabolism, albeit levels did not reach 
those of hES cells (Figure 3e).  
Together, these data indicated that VPA_AFS cells presented a higher dependance on 
glycolysis over OXPHOS, a feature associated with the pluripotent state in human and 
mouse cells25, 26. 
 
 
Expression of markers associated with pluripotency in VPA_AFS cells 
 
We used immunofluorescence-based staining to detect the expression of pluripotency-
associated proteins. We confirmed the flow cytometry results (Figure 1a) showing that 
endogenous OCT4 and NANOG proteins were expressed heterogeneously in VPA_AFS 
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cells (Figure 4a). Contrary to AFS cells, VPA_AFS cells also showed nuclear expression 
of DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B), ZFP42 (REX1), Oestrogen-
related receptor beta (ESRRB) (which is known to interact with OCT4A to positively 
regulate NANOG expression27), LIN28A (an RNA-binding protein highly expressed in 
mammalian ESCs28), and NODAL (which signalling controls NANOG expression and 
functions to maintain pluripotency in human iPS cells29 in most cells) (Figure 4a). 
Interestingly, ESRRB was expressed in VPA_AFS cells, with some cells also expressing 
NODAL, suggesting that VPA_AFS cells are in an intermediate state between naïve and 
primed pluripotency. In contrast to hES cells, but similar to epiblast stem (EpiS) cells, 
VPA_AFS cells had a high cloning efficiency and survived well when dissociated as 
single cells, which questions their developmental origin. As expected LIN28A was 
localized primarily to the cytoplasm in hES cells and absent in AFS cells whereas in 
VPA_AFS cells, we unexpectedly observed localization of LIN28A in the nucleus, 
outside the nucleoli. It has been reported that in the nuclei of hES cells and neural stem / 
progenitor cells, the RNA-binding protein musashi 1 (MSI1) enhances the localization of 
LIN28A to the nucleus to block the cropping and processing of pri let-7, which 
contributes to regulate miRNA biogenesis30, suggesting that VPA treatment may 
influence miRNA biogenesis and cell fate. 
 
 
VPA_AFS cells showed epigenetic modifications at histone 3 and 4 
 
Modification of lysines on the tails of histones H3 and H4 plays an important role in the 
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regulation of chromatin organisation and transcription31, and histone acetylation 
contributes to the maintenance of a pluripotent state, thereby improving the accessibility 
of DNA to transcriptional machinery required for transcription initiation32. Here, we 
show that compared to AFS cells, VPA treatment induced acetylation at three histone H3 
lysine residues, i.e. H3K9 (2.3; 2.4 and 2.3 time), K18 (1.3, 1.2 and1.3 time) and K56 
(1.7, 1.9 and 1.8 time) (Figure 4b). These histone modifications are associated with the 
pluripotent state, i.e. acetylated histone H3K56 controls transcriptional and translational 
processes by promoting pluripotency in ESCs33, whilst H3K18 acetylation is enriched at 
the promoters of OCT4, NANOG, SOX2 and KLF432, and H3K9 acetylation predict cell 
self-renewal34, 35 and reprogramming capacity36, 37.  
VPA_AFS cells also showed a slight 0.96 reduction in H4K16ac marks, which decrease 
promotes cellular longevity38, (Figure 4b). Finally, we observed a decrease (1.4; 1.2 and 
1.2 time) in the trimethylation of lysine 20 of H4, H4K20(3Me) (Figure 4b), which 
knockdown has been reported to increase the fraction of cells in S phase39-40. 
 
 
The effects of VPA treatment depended on endogeneous OCT4A activation 
 
OCT4A, which was not expressed in AFS cells (Figure 4a), was expressed in VPA_AFS 
cells (Figure 1a and Figure 4a). To determine whether VPA directly activated OCT4A 
expression, we silenced endogenous OCT4 gene expression in AFS cells and treated the 
cells with VPA (OCT4-shRNA VPA_AFS cells) (Figure 5a). We observed that VPA 
treatment failed to induce the expression of TRA-1-60, DNMT3B, LIN28A, NANOG, 
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NODAL, NR6A1 and REX1, as visualised by immunofluorescence using the same 
exposure time (Figure 4a and Figure 5a), although ESRRB remained expressed (Figure 
4a). To understand whether the absence of protein resulted from impeded translation or 
transcription, we assessed gene expression in (1) AFS cells, (2) VPA_AFS cells, (3) 
OCT4- shRNA VPA_AFS cells, (4) VPA_AFS cells following osteogenic differentiation 
and (5) hESCs cells (3 samples for each AFS-derived group) (Figure 5b). The results 
confirmed that silencing OCT4A inhibited VPA from inducing the transcriptional up-
regulation of PODXL, ZFP42, DNMT3B, NR6A1, NANOG, LIN28A and BMI1. These 
data highlight OCT4A reactivation as the bottlneck of VPA-induced modification of AFS 
cell identity towards an earlier state of cell fate potency.   
 
 
Single cell transcriptional profiling: homogenous expression of 14 pluripotency-
associated genes in VPA_AFS cells. 
 
We next investigated the heterogeneity of the VPA_AFS cell population using the 
Fluidigm microfluidics system platform41. This approach enabled us to simultaneously 
determine the expression level of 26 genes involved in pluripotency and of 10 lineage-
specific genes at the single-cell level in a total of 132 individual VPA_AFS cells from 
three different healthy donors and in hES cells (H1) (Figure 6a, Figure 7, Figure 8, 
Supplementary Figure 2, 3 and 4). The output of the runs is a 48x48 matrix of cycle 
threshold (Ct) values. All three samples showed similar gene expression patterns, as 
indicated by the similarity of the data among the three samples tested, indicating little 
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effect of the genotype. In all three samples, we determined that the VPA_AFS cell 
population was characterised by the homogeneous expression of OCT4, KLF4, SOX2, c-
MYC, NANOG and LIN28A, TDGF1, NR6A1, DNMT3B, ZFP42, PODXL, SALL4, 
LEFTY1, and LEFTY2 (Figure 6a), which are not expressed in AFS cells (Figure 5b). 
The co-expression of TRA-1-60, DNMT3B and REX1 has been reported to distinguish 
human fully reprogrammed iPSCs from partially reprogrammed cells41. The reactivation 
of NR6A1 has been reported to distinguish pluripotent iPS cells from incompletely 
reprogrammed cells, and absence of expression of NR6A1 in iPS cells results in 
maintenance of residual pluripotency gene expression during differentiation and improper 
differentiation in vitro and in vivo42. These results, combined with data obtained on 
protein expression, identify a transcriptional state for VPA_AFS cells and confirm the 
homogeneity of the VPA_AFS cell population. We noted that KLF4, which is already 
expressed in AFS cells (expression level is about 1% of that of hES cells), reached the 
same level as hES cells. However, we observed that the other markers were lower in 
VPA_AFS cells than in hES cells (Figure 6a). To explore this, we next used quantitative 
RT-PCR to compare the levels of expression of the core circuitry of pluripotency (OCT4, 
SOX2 and NANOG) in VPA_AFS cells to hES cells and iPS cells derived from AFS 
cells (using an episomal vector system) at different stages of reprogramming (Figure 6b). 
We show that expression of OCT4, SOX2 and NANOG remained lower in bona fide iPS 
cells than in hES cells, and that  VPA_AFS cells are equivalent to iPS cells between 14 
and 21 days of reprogramming (Figure 6b).    
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Single cell transcriptionanl profiling: heterogenous expression of 12 pluripotency-
associated genes in VPA_AFS cells. 
 
Other pluripotency-associated genes showed bimodal expression in VPA_AFS cells, with 
a distinct sub-goup of cells expressing the gene (Ct value <30) and a second sub-group 
showing weak or negligeable expression (Ct value >30). These markers included (1) the 
cyclin dependent kinase inhibition 1A and 2A CDKN1A and CDKN2A, (2) KLF5, (3) 
NODAL, (4) undifferentiated embryonic cell transcription factor 1 UTF1, (5) GDF3, (6) 
forkhead box protein 3 FOXD3, and (7) telomerase reverse transcriptase TERT (Figure 
7). 
However, developmental pluripotency associated 2 and 5 (DPPA2 and DPPA5), Krüppel-
like Factor 2 (KLF2) and fibroblast growth factor 4 (FGF4), were not expressed in 
VPA_AFS cells (Figure 7).    
Single embryonic stem cell analysis revealed a gradient of expression of pluripotency 
genes in the hES cell population, with cells at the top of the hierarchy showing increased 
self-renewal and expressing TDGF-1 and GDF343. We found that all the cells expressed 
TDGF-1, but only 72% of the cells expressed GDF3. It has also been shown that UTF1 is 
expressed in the few cells that become iPS cells, and hence can be used as an early 
marker to predict the ability of a cell to become fully reprogrammed44. Therefore, we 
investigated the proportion of cells that co-expressed GDF1 and UTF1 and found that 
67% VPA_AFS cells co-expressed both genes (defined by a Ct value <35), with a subset 
of 30% cells showing higher levels of expression (Ct value < 25) (Figure 7). We next 
investigated the molecular profile of the sub-population of cells co-expressing GDF3 and 
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UTF1 (GU+ cells), and compared it to the GDF-UTF- (GU-) cells for the 24 genes 
studied. Results showed that GU+ cells were not the cells expressing the heterogeneous 
cluster of pluripotency associated markers. However, GU+ cells expressed NODAL at a 
higher level (26.21.1 vs. 31.51.3, meanstd, P<0.01;) albeit still showing heterogeneity 
of the population (Supplementary Figure 3a). Performing the same transcriptome 
analysis on FOXD3+ cells revealed that FOXD3+ cells do not differ from FOXD3- cells 
for GDF3, NODAL, TERT, KLF2, but interestingly FOXD3+ cells showed higher levels 
of transcripts for the pluripotency markers FGF4 (36.60.8 vs. 38.20.3, P<0.01), UTF1 
(27.61.1 vs. 33.11.1, P<0.01), CDKN1A (25.61.2 vs. 29.81.2, P<0.05), CDKN2A 
(34.30.8 vs. 37.60.4, P<0.01), KLF5 (29.90.9 vs. 34.50.7, P<0.01), DPPA5 
(33.50.5 vs. 36.00.4, P<0.01), and DPPA2 (32.30.5 vs. 34.90.4, P<0.01) 
(Supplementary Figure 3b), indicating that FOXD3+ cells, which represent 47% of the 
whole VPA_AFS cell population correspond to the highest expressing cells of the 
heterogeneous cluster of pluripotency associated transcripts.  
 
 
Principle component analysis reveals the hierarchical organisation of VPA_AFS 
cells  
 
Principle component analysis of the data41 for the  pluripotency-associated genes studied 
(Figure 8) revealed a group of 8 core pluripotency genes (OCT4, KLF4, DNMT3B, 
SALL4, ZFP42, NR6A1, PODXL and SOX2) whose expression accounted for 68% of the 
observed variance between VPA_AFSC cells and AFS cells. A second group of 18 genes 
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(LEFTY1, LEFTY2, NODAL, NANOG, TDGF1, GDF3, UTF1, TERT, DPPA2, DPPA5, 
CDKN1A, CDKN2A, KLF2, KLF5, FOXD3, LIN28A, c-MYC and KLF5) explained 41% 
of the variance within the population.  
VPA_AFS cells showed low level of expression for HLA-A, HLA-B, and HLA-C, and 
for markers of specific lineages (NESTIN, MAP2, T, MSX1, SOX17, GATA4 and 
PAX6), and expression levels were not higher that those found in hES cells, confirming 
that VPA_AFS cells were in a pluripotent state (Supplementary Figure 4).  
 
 
VPA-mediated OCT4 promoter activation occured independently of GSK3 or 
PI3K/AKT/mTOR signaling 
 
VPA has previously show to enhance OCT4 promoter activity through activation of the 
PI3K/AKT/mTOR signalling pathway activated nuclear receptors in mouse myogenic 
cells58-59. Therefore, to gain mechanistic insight into the process of VPA reprogramming, 
we examined whether the same mechanisms was operating in VPA-AFS cells. However, 
treatment of AFS cells with 1mM VPA for 2 or 24 hours did not affect the levels of 
phospho-AKT or phospho-mTOR (Supplementary Figure 5a), indicating that activation 
of the PI3K/AKT/mTOR signalling pathway is not required for VPA to mediate OCT4 
activation and revert human AFS cells to pluripotency.  
VPA has pleiotropic effects which involve various pathways and multiple molecular 
targets such as glycogen synthase kinase 3 (GSK3)59. Here, we show that VPA 
treatment induced GSK3 inhibition in AFS cells, which could be recapitulated by 
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treating AFS cells with the GSK3 inhibitor CHIR99021 (Supplementary Figure 5b). 
However, treatment of AFS cells with CHIR99021 alone failed to revert the cells to 
pluripotency, indicating that the primary target of VPA in AFS cells is not GSK3 
(Supplementary Figure 5c). 
 
DISCUSSION 
 
 
Here, we established a correlation between the molecular regulation of the pluripotent 
state in human amniocytes cultured in hES cell conditions supplemented with VPA, and a 
description based on chromatin modifications, metabolism, cell cyle and gene expression 
to understand the molecular quality behind the behaviour of pluripotency.  
 
AFS cells, whose multipotent differentiation ability is routinely maintained in standard 
MSC cultured conditions, were adapted to feeder-free hES cell culture conditions before 
being treated with the histone deacetylase inhibitor VPA for 5-10 days, after which 
VPA_AFS cells were subsequently expanded for up to 30 days in feeder-free hES cell 
conditions. Short-term treatment with VPA reactivated the expression of endogenous 
OCT4A (along with its downstream targets), and maintained its expression level for as 
long as the cells were cultured in conditions maintaining the undifferentiated state of 
pluripotent cells. Contrary to AFS cells, VPA_AFS cells expressed TRA-1-60 and 
maintained its expression long-term. In addition to OCT4A and TRA-1-60, single cell 
analysis and immunostaining revealed that VPA_AFS cells homogeneously expressed 
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other pluripotency-associated genes, including DNMT3B, REX1, NANOG, ESSRB, 
LIN28A, KLF4, CMYC, SOX2, NR6A1, TDGF1 and SALL4, albeit the levels of 
expression found in VPA_AFS cells were lower than those observed for hES cells, 
explaining the results obtained on whole population transcriptome analysis, which 
established only a R=0.84 correlation between VPA_AFS cells and hES cells.  
 
These results indicate that the chromatin conformation of AFS cells is permissive to 
chemically-induced regulation of gene expression, and that the level of OCT4A 
expression reached in VPA_AFS cells was sufficient to confer the ability of the cells to 
form well-differentiated teratomas in vivo, and to differentiate into endoderm and 
ectoderm-derived lineages in vitro. It should be noted that we have experienced 
decreased efficiency of chemical reprogramming in response to repeated freeze-thaw 
cycles, likely due to its effects on the chromatin conformation of the cells.  
 
Although VPA_AFS cells fulfilled several functional, molecular, epigenetic and 
metabolic characteristics that have recently been described in De Los Angeles et al.45 as 
criteria of pluripotency, it is important to note that VPA_AFS cells were close, but 
different form hES cells. For example, only a subset of VPA_AFS cells expressed the 
pluripotency-associated genes NODAL, TERT, UTF1 and GDF3, with only 30% of the 
cells co-expressing UTF1 and GDF3. Interestingly, cells expressing FOXD3 showed 
higher transcript levels for other markers, such as CDKN1A, CDKN2A, FGF4, UTF1, 
KLF5, DPPA5 and DPPA2, suggesting they have reached a more advanced stage 
reprogramming, and it would be interesting to investigate the stability of these cells over 
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longer period of culture. In mouse embryonic fibroblasts, an alternative class of 
pluripotent cells independent of standard definitions of iPS state, referred as fuzzy cells, 
were recently characterised, indicating that pluripotent cells can exist as different and 
unique states that are alternative to hES cells46-49 The molecular events underlying 
functional pluripotency are not completely understood, and data from mouse and human 
studies indicate that pluripotency can be regained functionally without the cells reverting 
their cellular identity to hES cells. Interestingly, VPA_AFS cells were shown to express 
both ESRRB (a marker of naïve pluripotency) and NODAL (a marker of primed 
pluripotency, suggesting that the are in an intermediate state between naïve and primed 
pluripotency.  
 
We also demonstrated here that OCT4A was indispensible for VPA to modify the cellular 
identity of AFS cells. Although OCT4 has previously been identified as the bottleneck for 
cellular reprogramming50, the chemical replacement of OCT4 has yet only been achieved 
in mouse embryonic fibroblasts (MEFs) with a cocktail of seven small-molecule 
compounds51,52, or with the use of BrdU (bromodeoxyuridine)53. Our data indicate that 
AFS cells can be used as a model of human cells to study the chemical modulation of the 
pluripotency network via activation of endogenous OCT4A, allowing to correlate cell 
functionality with molecular profiling.  
 
The mechanisms by which VPA reactivated endogenous OCT4A expression in AFS cells 
remain speculative. VPA has pleiotropic effects on cell function, either promoting 
differentiation in vitro, facilitating the process of cellular reprogramming to 
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pluripotency2,19,54, suppressing reprogramming-induced senescence in human iPS cells55, 
inhibiting autophagy via modulation of the mTORC1 signaling pathway56, and promoting 
cell cycle progression and glycolysis57. Interestingly, VPA also enhances OCT4 promoter 
activity through the activation of the PI3K/Akt/mTOR signaling pathway in mouse 
myogenic cells58,59. It has also been established that mTOR complex 1 (mTORC1) 
signaling regulates histone H3K acetylation on lysine-5660-62 to promote nucleosome 
disassembly at promoter regions of OCT434. However, we found that in AFS cells, VPA 
did not activate OCT4 promoter through the PI3K/Akt/mTOR signaling pathway or 
GSK3 inhibition. However, the increase in acetylation of H3K9 and H3K56 marks 
observed in VPA_AFS cells suggest that activation of endogenous OCT4A might have 
been mediated by histone H3K56 acetylation. Elucidating the mechanisms by which VPA 
promoted endogenous OCT4 activity in human AFS cells provides a platform to study 
other small compounds which could act synergistically with VPA, paving the way for the 
development of chemical reprogramming of human adult somatic cells63.  
 
 
METHODS 
 
Cell culture. Human amniocytes, i.e. amniotic fluid stem (AFS) cells, were isolated after 
informed consent from the amniotic fluid at 12 weeks of gestation (normal pregnancy), 
which was obtained under ultrasound guidance and according to the ethical approval 
given by the Research Ethics Committees of Hammersmith & Queen Charlotte’s 
Hospitals (08/H0714/87) in compliance with national guidelines (Polkinghorne) for the 
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collection of fetal tissue for research. The AFS cells from three individuals with normal 
karyotype  (sample 1, 2 and 3) were selected for c-KIT expression and expanded (104 
cells/cm2) on plastic culture dishes without feeders in Dulbecco’s modified Eagle’s 
medium (DMEM-HG) (Invitrogen) supplemented with 10% fetal bovine serum (Biosera), 
2 mmol/l L-glutamine, 50 IU/ml penicillin and 50 mg/ml streptomycin (Gibco-BRL), at 
2 incubator. The cells were subsequently transferred onto Matrigel-
coated plates (Becton Dickinson) in NutriStem XF/FF (Stemgent) for 2-5 days, after 
which valproic acid (VPA, 1 mM; Sigma-Aldrich) or CHIR99021 (10 M, Stemgent) 
was added to the medium for a period of 5 days, after which the cells were subsequently 
cultured in NutriStem alone without VPA (VPA_AFS cells)13. NutriStem medium was 
replaced every 24 h. Human ES cell line H1 (WiCell Research Institute), was cultured in 
feeder-free conditions on Matrigel-coated plates in mTeSR (Stem Cell Technologies). 
NTERA2 cells (ATCC) were cultured in DMEM supplemented with 10% FBS). 
Microdissection passaging techniques were combined with type IV collagenase (1 mg/ml, 
Invitrogen) or dispase (1.5 mg/ml, Invitrogen) treatment to split cells at a ratio of 1:3. For 
comparative analysis to iPS cells at various stages of reprogramming, AFS cells were 
reprogrammed using an episomal mixture (Invitrogen kit A15960) over 50 days.  
 
Colony formation in soft agar. Anchorage-independent growth was determined by 
suspending VPA_AFS cells and NTERA2 cells (5 x 103 cells ) in DMEM containing 
10% FBS and 0.3% of low melting agarose (Gibco BRL). The cells were plated in 12-
well plates over a layer of solidified DMEM containing 10% FBS and 0.6% agarose. The 
medium was replaced every 3 days. Colonies were photographed after 3 weeks.  
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Transduction with OCT4-GFP and NANOG-GFP. We used OCT4-GFP lentivirus and 
NANOG-GFP lentivirus (Cellomics Inc) in which the GFP reporter gene is expressed 
from the OCT4 and NANOG promoter that is active when cells are in an undifferentiated 
state. If the OCT4 or NANOG promoter is gradually inactivated, the GFP reporter is 
down-regulated. For transduction with the lentivirus, AFS cells were plated in six-well 
plates with 2 ml D10 culture medium and then placed back in the CO2 incubator for 18 h 
prior to transduction. Aliquots of lentiviral stock were mixed with transduction medium 
(10 ug/ml polybrene in 2 ml growth medium). The cells were removed from the 
incubator, and the culture medium was aspirated and replaced with transduction medium 
containing the virus. The cultures were centrifuged at 1200 x g for 60 min at room 
temperature to increase infection efficiency. The plates were incubated at 37°C for 10 h 
in the CO2 incubator. The virus-containing transduction medium was then discarded and 
replaced with fresh growth medium. The cells were left to incubate for 24–48 h to enable 
the accumulation of the expressed protein in the target cells, after which the cells were 
selected using puromycin.  
 
OCT4 gene silencing. OCT4 was silenced in AFS cells using OCT4-short hairpin 
(sh)RNA (h) lentiviral particles (sc-36123, Insight Biotechnologies), which are provided 
as transduction-ready viral particles for gene silencing, following the manufacturer’s 
instructions. After transduction, AFS cells expressing the OCT4-shRNA were selected 
using puromycin.   
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Flow cytometry and confocal immunostaining. The antibodies used for flow cytometry 
and immuno-staining are listed in Supplementary Table 1. The OCT4 antibody (sc-5279, 
Santa Cruz) is a mouse monoclonal IgG raised against amino acids 1-134 of OCT4 of 
human origin, and does not cross–react with OCT4 isoform B. For flow cytometry, the 
cells were detached and dissociated into single cells using dispase (Sigma-Aldrich), and 
resuspended in FACS buffer (PBS, 1% Bovine Serum Albumin; 5 x 105 cells/100 ul 
FACS-buffer). For cell-surface staining, the AFS cells and VPA_AFS cells were replated 
as single cells in chamber slides to assess heterogeneity of expression and cellular 
localisation of antigens. The VPA-AFS OCT4-shRNA cells were directly stained on 
cover slips placed in the cell culture dishes. The cells were  stained with antibodies for 1 
fixed for 10 min in 0.01% PFA, washed twice with PBS, resuspended in permeabilisation 
buffer (PBS, 1% Triton) and stained as above. All samples were analysed via 
FACScalibur flow cytometry (Becton Dickinson) and analysed using CellQuest software. 
Negative controls were IgG or IgM primary antibody-specific isotypes. 
For confocal immuno-staining, the cells were fixed and stained as previously described7. 
Fluorescence confocal laser scanning microscopy images were collected on a Leica TCS 
SP5 (X1000 PL APO oil objective) and transferred to Adobe Photoshop (Adobe 
Systems). Secondary antibodies were donkey anti-mouse and anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories). hES cells (H1) served as positive controls. 
 
Quantitative RT-PCR. Total RNA was extracted using the RNeasy Mini RNA kit 
(Qiagen) and cDNA was synthesised using Pd(N)6 random hexamers (Amersham 
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Pharmacia Biotech) and 1 ml of 200U M-MLV Reverse Transcriptase in the presence of 
dNTPs (Promega), according to the manufacturer’s instructions. The generated cDNA 
was amplified using the ABI StepOne Sequence Detector system (Applied Biosystems) 
and TaqMan Assay probes, as listed in Supplementary Table 2 (Thermo Fisher 
Scientific). Samples were normalised against the internal control (18S).  
 
Single-cell quantitative RT-PCR. VPA_AFS cells were dissociated into single cells 
using dispase, resuspended in FACS buffer supplemented with 2% FBS (Biosera) and 
sorted into 96-well 0.2 ml PCR plates containing 5 μl of 2x CellsDirect Reaction Mix 
(Invitrogen) and 0.1 μl SUPERase-in (Ambion). Reverse transcription and specific 
transcript amplification were performed using SuperScript III Reverse Transcriptase / 
Platinum Taq Mix (Invitrogen) on the thermocycler as previously described45. The 
amplified cDNA was then loaded into Biomark 48.48 Dynamic Array chips using the 
Nanoflex IFC Controler (Fluidigm). We then used a microfluidic platform to conduct 
single cell qPCR in nanolitre reaction volumes using the Biomark machine. Threshold 
cycle (Ct), as a measurement of relative fluorescence intensity, was extracted by the 
Fluidigm Real-Time PCR Analysis software. The endogenous control gene was 18S. 
 
Carbon dioxide production: CO2 production was used as a marker of mitochondrial 
oxidative metabolism. The cells were cultured in 6-well plates at a density of 104 
cells/cm2. The culture media was then exchanged with media equivalent supplemented 
with [U-13C] D-glucose, and each well was covered with a glass microfibre filter disc 
(Whatman GF/A), soaked in 3.5 M NaOH and incubated for four hours. Following this, 
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500 μl culture medium was transferred to a 12-ml glass tube (Exetainer, Labco, UK), and 
glacial acetic acid (100 μl) was injected through the septum to release 13CO2 from 
bicarbonate. The filter paper was also removed and placed in a 12-ml glass tube, and CO2 
was released by the addition of glacial acetic acid. 13CO2/12CO2 was measured in the gas 
phase via isotope ratio mass spectrometry. The ratio of 13CO2 to 
12CO2 in bicarbonate is 
proportional to the quantity of oxidised glucose48. 
 
Fluorescent evaluation of ATP dynamics: One day prior to the experiment, AFS and 
VPA_AFS cells were seeded on 22 mm round borosilicate cover glasses and incubated at 
37°C, 5% CO2, to reach a confluence of approximatively 40% at imaging. The adherence 
of VPA_AFS cells to the glass surface was facilitated by coating the cover glasses with 
Matrigel. Cellular ATP levels were indirectly measured with the cell permeant green 
fluorescent Mg2+ indicator Magnesium Green™, which emission intensity increases 
without a shift in wavelength after binding to Mg2+. Briefly, the cells were loaded with 5 
μM Magnesium Green™ for 30 min at 37°C and 5% CO2. After loading, the cover 
glasses were washed three times with recording medium, and mounted within an 
Attofluor metal cell chamber for microscopy (Molecular ProbesTM, Thermo Fisher 
Scientific, A-7816). Continuous live imaging was carried out using a Zeiss LSM 510 
confocal laser scanning microscope (inverted configuration on an Axiovert 200 frame) 
equipped with a thermostated chamber (37°C) and a Fluar 40x/1.30 oil-immersion 
objective. A field of view with at least 10 cells was selected prior to time-series imaging 
of the Magnesium Green™ fluorescent signal. An argon-ion laser was used to excite the 
dye, and a HTF 488/543 dichroic mirror with a BP 500/550 band-pass filter was used to 
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capture the emitted fluorescence. The settings were held constant between experiments 
and were chosen to reduce photobleaching of the fluorophore (laser power: 1%). The 
pinhole was set to produce an optical slice of ~2 μm. After the administration of 
oligomycin (2.5 μg/ml) to block (1) the proton flux through the F1F0-ATPase and (2) 
cytosolic ATP depletion, images were acquired every second to follow the time-course of 
cytosolic ATP depletion. Regions of interest were demarcated by selecting the entire cell 
surface area, and the average intensity of the florescent signal was measured. Raw data 
were averaged in Prism 6, and the slopes of the generated curves were calculated in 
Microsoft Excel 10 through linear regression. Greater Mg2+ availability induces a faster 
rate of increase in Magnesium Green fluorescence intensity; thus the slope of the graph 
represents an indirect method to evaluate ATP depletion. 
 
Western blotting: Protein lysates were generated using standard lysis buffer (50 mM 
Tris 7.5pH, 150 mM NaCl, 1 mM EDTA) containing 1% SDS with sonication to disrupt 
genomic DNA. Twenty-five ug β-mercaptoethanol denatured lysates were separated on a 
12.5% -PAGE gel and blotted onto a Protran nitrocellulose transfer membrane 
(Whatman, Life Sciences). The membrane was blocked in 5% milk PBS-T (phosphate-
buffered saline with 0.1% Tween-20) and immunoprobed with antibodies raised against 
different peptides containing different histone modifications (H3K9ac Abcam Cell 
Signalling 96715; H3K18ac Abcam 1191, H3K56ac epitomics 2134-1, H4K20me3 
Millipore 07-463, H3 Abcam 10158 and H4 Abcam 1971 loading controls). The 
secondary antibodies used were goat anti-rabbit conjugated to horseradish peroxidase 
(HRP) (Dako) and rabbit anti-mouse-HRP (1:5000) (Dako). The experiments were 
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performed in triplicate. Bands were quantitated via direct scanning of the western blot 
films with a HP Scanjet 4890 and quantified using ImageJ software. For analysis of the 
PI3K/AKT/mTOR signalling pathway, the antibodies for phosphorylated AKT (pAKT), 
phosphorylated mTOR (pmTOR) and total mTOR antibodies were purchased from from 
Cell Signaling (40585, 55365, 29725) and the antibody for total AKT was purchased 
from Abcam (ab8932). 
 
Cell cycle analysis: Cells were washed with PBS, dissociated using TrypLE (Life 
Technologies), then washed twice with PBS. The supernatant was then discarded and the 
cells fixed in ice cold 70% ethanol for 30 mins at 4°C. The cells were then washed again, 
centrifuged at 850 g and resuspended in 100 µl 100 µg/ml RNAse A (Qiagen) + 400 µl 
50 µg/ml propidium iodide (Sigma). The cells were incubated on ice in the dark for 10 
minutes prior to analysis using the FACScalibur as described above.  
 
Statistical analysis: Statistical analysis was performed using InStat Version 3.0a 
statistical software (GraphPad Software, La Jolla, CA ). P < 0.05 was significant. 
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FIGURE LEGENDS 
 
Figure 1 | VPA_AFS cells are similar yet different from hES cells. (a) Flow cytometry 
for expression of the cell surface markers TRA-1-60, TRA-1-81, SSEA3, and for the 
nuclear markers NANOG and OCT4 in hES cells, AFS cells (whole population) and 
VPA_AFS cells (whole population). The red tracing shows the isotype control and the 
blue tracing shows the primary antibody. (b) Scatter plot (log2) of two hES cell lines (H1 
and H9) and of VPA_AFS cells (whole population) vs H1 and VPA_AFS cells vs H9; 
and heatmap of pluripotency associated genes generated via similarity measure Pearson 
correlation (color scaling per row/gene) using the transcriptome profiling data of the cells 
acquired previously using the Human Ref-8 v3.0 expression BeadChip platform (NCBI 
Gene expression omnibus, GSE26940).  
 
Figure 2 | Efficiency of the VPA treatment. (a) AFS cells transfected with OCT4-GFP 
or NANOG-GFP reporters genes were cultured on plastic culture dishes in growth 
medium composed of DMEM supplemented with 10% FBS before being transferred on 
Matrigel-coated dishes in Nutristem medium for 7 to 14 days prior to exposure to 1 mM 
VPA for 5 days (VPA_AFS Cells). TRA-1-60+ cells were subsequently single-cell sorted 
into four 96-well plates, and cultured for another 28 days in Nutristem (supplemented 
with a ROCK inhibitor to increase cloning efficiency) on Matrigel. In parallel, the whole 
VPA_AFS cell population was also maintained in culture for 28 days. (b) The number of 
OCT4-GFP+ or NANOG-GFP+ clones was monitored at 7, 14 and 28 days in the 96-well 
plates, and the GFP intensity was recorded at 7 and 28 days using an optical plate reader. 
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(c) TRA-1-60 expression was assessed by flow cytometry (the red tracing shows the 
isotype control and the blue tracing shows the primary antibody) in the VPA_AFS cell 
population after 28 days in culture in Nutristem. (d) OCT4-GFP was validated using 
immunosfluorescence in hES cells using OCT4A-specific antibody. 
 
Figure 3 | Cell size, cell cycle and metabolism of AFS and VPA_AFS cells. (a) Phase 
contrast images of VPA_AFS cells (left panel, x40 magnification) and confocal immuno-
fluorescence showing the morphology of the cells growing as compact colonies (right 
panel). Nuclei stained with DAPI (blue). Actin filaments stained with Alexa Fluor 594 
Phalloidin (red). Scale bar 50μm. (b) Flow scatter and histogram showing differences in 
the relative size of parental AFS cells (pink) and VPA_AFS cells (blue). (c) Flow 
cytometry of AFS cells, VPA_AFS cells expanded for 28 days in NutriStem on Matrigel, 
and hES cells showing DNA stained with propidium iodide. G1 indicates cells with 2n 
cellular DNA content, S indicates cells undergoing mitosis, and G2/M indicates cells with 
4n cellular DNA content. (d) Magnesium green fluorescence intensity staining, as a 
function of ATP levels, over time for parental AFS cells and VPA_AFS cells following 
the addition of 2.5 μg/ml OLIGO. Representative traces depicting oligomycin-induced 
ATP depletion for parental AFS cells and VPA_AFS cells. Cells were loaded with Mg2+ 
indicator Magnesium GreenTM and AM to obtain an indirect measurement of cellular 
ATP levels over time. Upon the addition of oligomycin (2.5 μg/ml), a rapid increase in 
Magnesium GreenTM emitted fluorescence is observable in AFS cells. The bar chart on 
the right reports the average slopes of increase in Magnesium GreenTM fluorescence for 
AFS cells and VPA_AFS cells (n = 3, p < 0.005). (e) Oxidative phosphorylation studied 
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using carbon isotope labelling of [U-13C] glucose, followed by CO2 release, isotype 
analysis and quantification in AFS cells, VPA_AFS cells, hES cells, and AFS cells 
differentiated for 2 weeks down the osteogenic lineaeg. *** P<0.001. 
 
Figure 4 | VPA_AFS cells gain the expression of pluripotency markers and undergo 
histone modifications. (a) Confocal immuno-fluorescence showing expression of 
DNMT3B, REX1, OCT4A, NANOG, ESRRB, LIN28A, and NODAL stained with FITC 
(green) in hES cells, AFS cells, VPA_AFS cells and OCT4-shRNA cells using the same 
exposure time. The nuclei are stained with DAPI (blue). Actin filaments are stained with 
Alexa Fluor 594 Phalloidin (red). Scale bar 50μm. (b) Western blotting for histone 
modification detection in AFS cells and VPA_AFS cells. Lysates were made and western 
blot was performed with antibodies against acetylated and methylated lysines located on 
the N-terminal histone tails and compared with the total H3 and H4 loading controls. 
 
Figure 5 | Blocking OCT4A expression in AFS cells prevents VPA from inducing the 
up-regulation of pluripotency markers. (a) Flow cytometry showing OCT4 and TRA-
1-60 expression in OCT4-shRNA VPA_AFS cells. The red tracing shows the isotype 
control and the blue tracing shows the primary antibody. (b) Quantitative RT-PCR for the 
housekeeping genes 18S and ACTIN,  and for the pluripotency markers OCT4A, PODXL, 
ZFP42, DNMT3B, NR6A1, TGFB1, NANOG, LIN28A, and BMI-1 in AFS cells (n = 3, 
blue bars), VPA_AFS cells (n = 3, red bars), OCT4-shRNA VPA_AFS cells (n = 3, 
yellow bars), AFS cells differentiated down the osteogenic lineage (n = 3, green bars), 
and hES cells (n=2, black bars)., error bars are s.e.m. 
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Figure 6 | Single-cell transcriptional profiling: homogenous expression of 14 
pluripotency-associated genes in VPA_AFS cells. (a) Population distribution for 3 
different VPA_AFS cell samples (S1, S2 and S3, 46 cells per sample) and hES cells 
showing homogeneity in the expression of 14 genes associated with pluripotency (OCT4, 
KLF4, SOX2, CMYC, NANOG, LIN28A, TDGF1, NR6A1, DNMT3B, REX1, PODXL, 
SALL4, LEFTY2 and LEFTY1). Each point represents the expression value of a single 
cell. The horizontal axis represents the Ct value. The red bar indicates the mean Ct value. 
(b) Quantitative real-time RT-PCR for OCT4, SOX2 and NANOG in hES cells (n = 3, 
blue bars), iPS cells at day 14 (n = 3, red bars), day 21 (n = 3, yellow bars), fully 
reprogrammed iPS cells (n = 3, green bars) and VPA_AFS cells (n = 3, black bars). 
Housekeeping genes for normalisation were GAPDH and 18S. error bars are s.e.m. 
 
Figure 7 | Single-cell transcriptional profiling: heterogenous expression of 12 
pluripotency-associated genes in VPA_AFS cells. (a) Population distribution for 3 
different VPA_AFS cell samples (S1, S2 and S3, 46 cells per sample) and hES cells 
showing heterogeneity in the expression of 12 genes associated with pluripotency 
(CDKN1A, CDKN2A, KLF5, NODAL, UTF1, GDF3, FOXD3, TERT, KLF2, DPPA2, 
DPPA5, and FGF4). The red bar indicates the mean Ct value. (c) Distribution of Ct 
values for UTF1 (horizontal axis) and GDF3 (vertical axis) in VPA_AFS cells.  
 
Figure 8 | Principal component analysis of VPA_AFS cells. Principal component 
analysis for 26 pluripotency genes in 3 samples (138 cells analysed per gene) and 
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corresponding biplots. 
 
Supplementary Figure 1 | Colony formation in soft agar assay. Images showing 
absence of formation of colonies for VPA_AFS cells (left panels) and presence of 
colonies for NTERA2 cells (right panels) cultured in soft agar for 3 weeks.  
 
Supplementary Figure 2 | Heatmaps for 3 independant AFS cell samples. Array 
showing gene expression profiling for 46 single VPA_AFS cells  for 27 pluripotency 
genes and 13 lineage specific genes. 
 
Supplementary Figure 3 | Single-cell transcriptional profiling in cell subsets. 
Population distribution for UTF+GDF+ (GU+) and UTF-GDF- (GU-) cells (a) and 
FOD3+ and FOD3- cells (b), showing homogeneity in the expression of UTF1, GDF3’ 
CDKN1A, CDKN2A, KLF5, NODAL, FOXD3, TERT, KLF2, DPPA2, DPPA5, and 
FGF4. The red bar indicates the mean Ct value. * P < 0.01, Student’s t test.  
 
Supplementary Figure 4 | Single cell transcriptional profiling: expression of lineage-
specific genes in VPA_AFS cells. Population distribution for 3 different VPA_AFS cell 
samples (S1, S2 and S3, 46 cells per sample) showing homogeneity in the expression of 
NESTIN, HLA-A, HLA-C, SOX17 and GATA4, and a higher degree of variability in the 
expression of HLA-B, MAP2, T, MSX1, and PAX6. Each point represents the expression 
value of a single cell. Horizontal axis represents Ct value. The red bar indicates the mean 
Ct value. 
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Supplementary Figure 5 | Mechanistic insight into VPA-induced reprogramming. 
(a) Western blotting for pAKT and pmTOR in AFS cells with or without 1mM VPA 
treatment for 2h and 24h. The right panels show quantification of bands intensity, 
measure with Image J software. (b) Confocal immuno-fluorescence showing expression 
of GSK3 stained with FITC (green) in hES cells, AFS cells, VPA_AFS cells and AFS 
cells treated with 10 M CHIR99021 for 5 days. The nuclei are stained with DAPI (blue). 
Actin filaments are stained with Alexa Fluor 594 Phalloidin (red). Scale bar 50μm. (c) 
Flow cytometry showing TRA-1-60 expression in VPA_AFS cells treated with 
CHIR99021. The red tracing shows the isotype control and the blue tracing shows the 
primary antibody. 
 
 
Supplementary table 1 | List of primary antibodies used for flow cytometry or confocal 
immuno-staining.  
 
Supplementary table 2 | List of Taqman assay ID used in this study.  
 
 
